Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects

NMR in Biomedicine

Volumn 24, Issue 5, 2011, Pages 473-482

  Lemasson, Benjamin ^a,b,c   Christen, Thomas ^b,c   Tizon, Xavier ^a   Farion, Régine ^b,c   Fondraz, Nadège ^b,c   Provent, Peggy ^a   Segebarth, Christoph ^b,c   Barbier, Emmanuel L ^b,c   Genne, Philippe ^a   Duchamp, Olivier ^a   Remy, Chantal ^b,c  

^a Oncodesign Biotechnology   (France)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

Apparent diffusion coefficient (ADC) of water; Blood volume fraction (BVf); Brain tumor; Contrast enhancement MRI; Therapies; Vessel size index (VSI)

Indexed keywords

APPARENT DIFFUSION COEFFICIENT (ADC) OF WATER; BLOOD VOLUME FRACTION (BVF); BRAIN TUMOR; CONTRAST ENHANCEMENT; THERAPIES; VESSEL SIZE;

BLOOD; DRUG THERAPY; HEMODYNAMICS; MAGNETIC RESONANCE IMAGING; RATING; SURFACE DIFFUSION; TITRATION;

TUMORS;

BIOLOGICAL MARKER; CARMUSTINE; SORAFENIB; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; CANCER TRANSPLANTATION; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DRUG CYTOTOXICITY; DRUG EFFECT; GLIOMA; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; MICROVASCULATURE; MULTIPARAMETRIC MRI; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZENESULFONATES; BLOOD VOLUME; CARMUSTINE; CELL DEATH; CELL LINE, TUMOR; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROVESSELS; MODELS, BIOLOGICAL; PYRIDINES; RATS; RATS, NUDE; STAINING AND LABELING; SURVIVAL ANALYSIS;

RATTUS;

EID: 79958844267     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1611     Document Type: Article

References (36)

1. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007; 8: 610-622.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002; 29 (6 Suppl 16): 15-18.
3. Burnet NG, Lynch AG, Jefferies SJ, Price SJ, Jones PH, Antoun NM, Xuereb JH, Pohl U. High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother. Oncol. 2007; 85: 371-378.
4. Tabatabai G, Stupp R. Primetime for antiangiogenic therapy. Curr. Opin. Neurol. 2009; 22: 639-644.
5. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr. Opin. Neurol. 2008; 21: 736-744.
6. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology, 2009; 72: 1217-1222.
7. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, Reznek R, Society ICI. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br. J. Cancer, 2004; 90: 2256-2260.
8. Gagner J-P, Law M, Fischer I, Newcomb EW, Zagzag D. Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol. 2005; 15: 342-363.
9. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009; 6: 327-338.
10. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc. Natl. Acad. Sci. USA, 2005; 102: 16, 759-16, 764.
11. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, Chenevert TL. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol. Cancer Ther. 2003; 2: 581-587.
12. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics, 2009; 6: 465-477.
13. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J. Magn. Reson. Imaging, 2007; 26: 235-249.
14. Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, Gillespie GY. High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: sequential small molecule and SPIO dynamic contrast agent MRI. Magn. Reson. Med. 2009; 61: 615-625.
15. Beaumont M, Lemasson B, Farion R, Segebarth C, Rémy C, Barbier EL. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI. J. Cereb. Blood Flow Metab. 2009; 29: 1714-1726.
16. Sorensen AG, Batchelor TT, Zhang W-T, Chen P-J, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A 'vascular normalization index' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009; 69: 5296-5300.
17. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol. Ther. 2008; 7: 496-501.
18. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W, Kiessling F. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J. Magn. Reson. Imaging, 2009; 29: 1125-1133.
19. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J. Cereb. Blood Flow Metab. 2009; 29: 853-860.
20. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007; 11: 83-95.
21. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006; 5: 835-844.
22. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol. Cancer Ther. 2008; 7: 3519-3526.
23. Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci. Lett. 2010; 478: 165-170.
24. Jacquier A, Wendland M, Do L, Robert P, Corot C, Higgins CB, Saeed M. MR imaging assessment of the kinetics of P846, a new gadolinium-based MR contrast medium, in ischemically injured myocardium. Contrast Media Mol. Imaging, 2008; 3: 112-119.
25. Redgate ES, Deutsch M, Boggs SS. Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns. Lab. Anim. Sci. 1991; 41: 269-273.
26. Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, Barbier EL. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed. 2008; 21: 1043-1056.
27. Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007; 188: 1622-1635.
28. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006; 116: 2610-2621.
29. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004; 165: 35-52.
30. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TPL. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J. Magn. Reson. Imaging, 2004; 20: 138-144.
31. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005; 307: 58-62.
32. Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Shibuya M, Isae T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006; 66: 9134-9142.
33. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn. Reson. Med. 1995; 33: 564-568.
34. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med. 1991; 17: 357-367.
35. Barbier EL, Lamalle L, Décorps M. Methodology of brain perfusion imaging. J. Magn. Reson. Imaging, 2001; 13: 496-520.
36. He X, Yablonskiy DA. Quantitative BOLD: mapping of human cerebral deoxygenated blood volume and oxygen extraction fraction: default state. Magn. Reson. Med. 2007; 57: 115-126.